Literature DB >> 1829739

Predictors of antidepressant treatment outcome in melancholia: psychosocial, clinical and biological indicators.

J Vallejo1, C Gasto, R Catalan, A Bulbena, J M Menchon.   

Abstract

Predictive variables of response to imipramine and to phenelzine at 6 weeks and 6 months were studied in 116 patients suffering from major depression with melancholia (DSM-III). Several sociodemographic, clinical, and biological variables were studied. For imipramine-treated patients, high social support predicted a better response at 6 weeks, while development of hypomania during follow-up was associated with a better response at 6 weeks; absence of life events during the 6-month follow-up and initial non-suppression of dexamethasone predicted a better outcome at 6 months. For phenelzine-treated patients, development of hypomania during follow-up was associated with a better outcome at 6 months and absence of life events prior to the onset of the episode was associated with a worse outcome at 6 months.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1829739     DOI: 10.1016/0165-0327(91)90036-r

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  5 in total

1.  Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial.

Authors:  Edward S Friedman; Lori L Davis; Sidney Zisook; Stephen R Wisniewski; Madhukar H Trivedi; Maurizio Fava; A John Rush
Journal:  Eur Neuropsychopharmacol       Date:  2011-09-14       Impact factor: 4.600

2.  Support and undermining in interpersonal relationships are associated with symptom improvement in a trial of antidepressant medication.

Authors:  Nataria T Joseph; Hector F Myers; Jonathan R Schettino; Natasha T Olmos; Consuelo Bingham-Mira; Ira M Lesser; Russell E Poland
Journal:  Psychiatry       Date:  2011       Impact factor: 2.458

3.  What moderator characteristics are associated with better prognosis for depression?

Authors:  Madhukar H Trivedi; David W Morris; Ji-Yang Pan; Bruce D Grannemann; A John Rush
Journal:  Neuropsychiatr Dis Treat       Date:  2005-03       Impact factor: 2.570

4.  Study protocol for the randomised controlled trial: antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study).

Authors:  R Hamish McAllister-Williams; Eleanor Smith; Ian M Anderson; Jane Barnes; Peter Gallagher; Heinz C R Grunze; Peter M Haddad; Allan O House; Tom Hughes; Adrian J Lloyd; Elaine M M McColl; Simon H S Pearce; Najma Siddiqi; Baxi Sinha; Chris Speed; I Nick Steen; June Wainright; Stuart Watson; Fiona H Winter; I Nicol Ferrier
Journal:  BMC Psychiatry       Date:  2013-08-03       Impact factor: 3.630

5.  Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials.

Authors:  Angelo Sambunaris; Carl Gommoll; Changzheng Chen; William M Greenberg
Journal:  Int Clin Psychopharmacol       Date:  2014-07       Impact factor: 1.659

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.